WO2007078117A1 - Extract of gentianae macrophyllae radix for the treatment of dermatological diseases - Google Patents
Extract of gentianae macrophyllae radix for the treatment of dermatological diseases Download PDFInfo
- Publication number
- WO2007078117A1 WO2007078117A1 PCT/KR2006/005868 KR2006005868W WO2007078117A1 WO 2007078117 A1 WO2007078117 A1 WO 2007078117A1 KR 2006005868 W KR2006005868 W KR 2006005868W WO 2007078117 A1 WO2007078117 A1 WO 2007078117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- gentianae macrophyllae
- macrophyllae radix
- treatment
- radix
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 24
- 201000004681 Psoriasis Diseases 0.000 claims description 12
- 230000036566 epidermal hyperplasia Effects 0.000 claims description 7
- 239000008177 pharmaceutical agent Substances 0.000 claims description 7
- 210000003491 skin Anatomy 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 210000004927 skin cell Anatomy 0.000 claims description 3
- 229940000033 dermatological agent Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 14
- 238000000605 extraction Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000012454 non-polar solvent Substances 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- 229940124595 oriental medicine Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- -1 gentianol Chemical compound 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 2
- KFJQLAOTTSPBMT-UHFFFAOYSA-N 6-methyl-3,4-dihydropyrano[3,4-c]pyridin-1-one Chemical compound C1COC(=O)C2=C1C=C(C)N=C2 KFJQLAOTTSPBMT-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- DFNZYFAJQPLJFI-UHFFFAOYSA-N gentianine Chemical compound O=C1OCCC2=C1C=NC=C2C=C DFNZYFAJQPLJFI-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 1
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 1
- XOXYHGOIRWABTC-UHFFFAOYSA-N Gentisin Natural products C1=C(O)C=C2C(=O)C3=C(O)C=C(OC)C=C3OC2=C1 XOXYHGOIRWABTC-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 102000005706 Keratin-6 Human genes 0.000 description 1
- 108010070557 Keratin-6 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000010907 stover Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Definitions
- the present invention relates to an extract of Gentianae macrophyllae radix useful for the treatment of dermatological diseases, in particular, an extract of Gentianae macrophyllae radix which has an excellent inhibitory effect on epidermal hyperplasia thus being useful for the prevention and treatment of dermatological diseases such as psoriasis.
- Psoriasis is a dermatological disease which is characterized in that a patient's epidermal surface is covered with whitish scaly skin cells thus clearly marking its boundary with the neighboring skin, and also producing scabs with various sizes in red spots which grow bigger as time passes. This disease often develops on the skins of elbows, knees, buttocks, head and also on hands and soles. The above skin areas appear to be more frequently affected than other parts of a body. Psoriasis develops regardless of a sex and occurs most highly in people in their early 20s.
- Psoriasis is a progressive and chronic disease, which often recurs and is hardly cured completely once it is developed. Although many people have been suffering from chronic dermatological diseases such as psoriasis, there has not been developed any good cure for the treatment of the above diseases and only deterioration of the seriousness of the above diseases has been merely wished. Therefore, it is essential to develop a good therapeutic pharmaceutical drug with an excellent mechanism of action for the treatment of the above diseases. However, neither the main cause nor the substance, which may trigger the development of cures for the diseases, has been clearly identified and thus the developmental procedure of the therapeutic pharmaceutical agent has been long deterred.
- the Gentianae macrophyllae radix used in the present invention is a perennial plant having a height of 40 - 60 cm and a strong but unelastic root. It is widely distributed in China such as Heilongjiang, Liaoning, Hebei, Heinan, Sichuan provinces. They are collected in Spring and Autumn.
- the plants may be dried in the sunlight after removing stovers, fibrous roots and soils, or dried after piling them together. In general, when they become reddish yellow or yellowish gray they are scattered and dried in the sunlight.
- the present invention relates to a therapeutic pharmaceutical agent comprising an extract of Gentianae macrophyllae radix as an active ingredient for the treatment of epidermal hyperplasia.
- the present invention relates to an extract of crude Gentianae macrophyllae radix having an excellent inhibitory effect on epidermal proliferation of skin thus being useful for the prevention and treatment of dermatological diseases such as psoriasis.
- the present invention relates to a method of preparing an extract of crude Gentianae macrophyllae radix comprising:
- Gentianae macrophyllae radix is added with water or an aqueous alcohol solution and extracted under reflux for 2-5 hours.
- the amount of water used is preferably in the range of 10-15 times of the weight of the Gentianae macrophyllae radix.
- the mixture undergoes filtration and the resulting filtrate is collected.
- water or an aqueous alcohol solution in the amount of 7-12 times of the weight of the Gentianae macrophyllae radix is added to the resulting residue, and the mixture is heated.
- the mixture is reextracted for 2-5 hours, filtered and the resulting filtrate is combined with the filtrate obtained previously thereby increasing the extraction efficiency.
- extraction is performed twice, i.e., first extraction and re- extraction. This is because a single extraction in the case of a large scale production of extract may not guarantee relatively high extraction efficiency due to a great loss in water content contained in the crude drug itself during the extraction process, and by conducting a reextraction the resulting extract efficiency can be greatly increased.
- the extract obtained by the double extraction using water or an aqueous alcohol solution is filtered and concentrated. Then impurities such as unnecessary proteins, polysaccharides, and fatty acids contained in the resulting concentrated filtrate are purified.
- the filtrate is purified by fractionation of the filtrate 2-4 times and obtaining a solvent fraction using a low grade alcohol or a nonpolar solvent which is equal in amount to that of the filtrate.
- a low grade alcohol is preferably a C1-C6 alcohol, more preferably butyl alcohol, propyl alcohol and isopropyl alcohol.
- a nonpolar solvent may be selected from the group consisting of ethyl acetate, dichloro methane, chloroform, carbon tetrachloride, and methylethylketone.
- the amount of the low grade alcohol or the nonpolar solvent is less than that of the filtrate, it forms granules from unnecessary components such as fatty acid thereby preventing a smooth separation of layers and also decreasing the content of active ingredients contained in the extract.
- the purpose of using water in performing azeotropic concentration in this process is to effectively control the amount of the residual low grade alcohol for use of a crude drug extract as a source for a pharmaceutical agent.
- the above extract then undergoes lyophilization and the final extract in the form of powder is obtained.
- the extract has an excellent inhibitory effect on epidermal proliferation and is thus expected to be useful as a therapeutic pharmaceutical agent for the prevention and treatment of dermatological diseases such as psoriasis.
- the extract of Gentianae macrophyllae radix prepared according to the present invention is formulated in the form of tablets, capsules, injections and the like.
- the ratio between the combined amount of excipients, such as lactose, microcrystalline cellulose, magnesium stearate, and the amount of the above extract is preferred to be 2: 1 to attain a desired pharmaceutical activity for the prevention and treatment of dermatological diseases.
- Crude drugs themselves may be directly used as pharmaceutical agents. However, they may be combined with pharmaceutically acceptable additives such as a carrier, a forming agent, or a diluent to be prepared in the form of powder, granules, capsules, injections and the like.
- pharmaceutically acceptable additives such as a carrier, a forming agent, or a diluent to be prepared in the form of powder, granules, capsules, injections and the like.
- the extract of Gentianae macrophyllae radix has been long used as a food or an oriental medicine. There has been no particular limitation on its dosage but its dosage may vary depending on the rate of body absorption, body weight, age, sex, health conditions, dosage time, type of administration, excretion rate, seriousness of diseases of a subject.
- the extract of Gentianae macrophyllae radix is preferably administered about 0.1 - 10 mg/kg. Therefore, the extract comprising the active ingredient of the present invention may be manufactured in consideration of the effective dosage.
- the formulated unit dosage prepared thereof can be administered once or a few times at regular intervals daily by means of specialized administration, upon necessity, according to the advice and/or the request of a specialist or a supervisor who monitors and supervises drug administration.
- Each group consisted of 2 rats. They were orally respectively administered with the extract of Gentianae macrophyllae radix prepared in Preparation Examples 1 and 2 with a dosage of 1 g/kg/mL once. After the administration, the rats were observed of their deaths, clinical symptoms, and weight changes. Further, hematological test and hematobiochemical test were conducted and abnormalities on abdominal and pectoral organs were observed by naked eyes via autopsies. As a result, no significant clinical symptoms or dead rats were found, and also no toxicity was observed from the weight changes, blood test, hematobiochemical test and autopsies.
- Gentianae macrophyllae radix of the present invention via wet granulation and dry granulation according to the following formulation.
- Epidermal formulation was prepared by using the extract of crude Gentianae macrophyllae radix prepared according to the present invention.
- the extract of Gentianae macrophyllae radix prepared according to the present invention has an excellent inhibitory effect on epidermal hyperplasia and is thus speculated to be very useful for the prevention and treatment of dermatological diseases such as psoriasis.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Disclosed is an extract of Gentianae macrophyllae radix useful for the treatment of dermatological diseases, in particular, an extract of Gentianae macrophyllae radix which has an excellent inhibitory effect on epidermal proliferation of skin thus being useful for the prevention and treatment of dermatological diseases.
Description
Description EXTRACT OF GENTIANAE MACROPHYLLAE RADIX FOR
THE TREATMENT OF DERMATOLOGICAL DISEASES
Technical Field
[1]
[2] The present invention relates to an extract of Gentianae macrophyllae radix useful for the treatment of dermatological diseases, in particular, an extract of Gentianae macrophyllae radix which has an excellent inhibitory effect on epidermal hyperplasia thus being useful for the prevention and treatment of dermatological diseases such as psoriasis.
[3]
Background Art
[4]
[5] Psoriasis is a dermatological disease which is characterized in that a patient's epidermal surface is covered with whitish scaly skin cells thus clearly marking its boundary with the neighboring skin, and also producing scabs with various sizes in red spots which grow bigger as time passes. This disease often develops on the skins of elbows, knees, buttocks, head and also on hands and soles. The above skin areas appear to be more frequently affected than other parts of a body. Psoriasis develops regardless of a sex and occurs most highly in people in their early 20s.
[6] Although the direct cause of psoriasis has not been identified, it appears that the disease may be developed by combinatory reasons of genetic factors as well as environmental conditions such as hormonal change, stress, trauma, infectious disease such as tonsillitis, weather, dryness skin, drugs, genetic history and the like. Psoriasis, although being developed by various reasons as mentioned above, is specifically caused by the extremely fast growth of skin cells, which is about 6-7 times faster than those of normal cells, thereby inducing the peeling-off of the excessive and incompletely grown whitish scaly skin of a plurality of piled-up layers of keratinized cells.
[7] Psoriasis is a progressive and chronic disease, which often recurs and is hardly cured completely once it is developed. Although many people have been suffering from chronic dermatological diseases such as psoriasis, there has not been developed any good cure for the treatment of the above diseases and only deterioration of the seriousness of the above diseases has been merely wished. Therefore, it is essential to develop a good therapeutic pharmaceutical drug with an excellent mechanism of action for the treatment of the above diseases. However, neither the main cause nor the
substance, which may trigger the development of cures for the diseases, has been clearly identified and thus the developmental procedure of the therapeutic pharmaceutical agent has been long deterred.
[8] Recent clinical studies on tissues of dermatological lesions in patients with the above-mentioned dermatological diseases disclosed infiltration of eosinophils, mast cells and neutrophils, and abnormal growth of skin epidermis (epidermal hyperplasia, epidermal hyperproliferation). The main reasons of the above symptoms were reported to be closely associated with epidermal differentiation as in keratin 6 and abnormal expression of genes which are involved in epidermal hyperplasia (Sugimura et al., Br. J. Dermatol. 152, 146-149, 2005). Since the epidermal proliferation is one of the major factors causing the dermatological diseases, any substance that can inhibit epidermal proliferation may be used as a therapeutic agent to treat dermatological diseases such as psoriasis.
[9] Nonetheless, not many chemical drugs have been known to inhibit epidermal proliferation, and they are not free from side effects when used for a long period of time. Therefore, it has been long wished to discover an extract isolated from herbal medicines which may prevent side effects even with a long term use.
[10] The Gentianae macrophyllae radix used in the present invention is a perennial plant having a height of 40 - 60 cm and a strong but unelastic root. It is widely distributed in China such as Heilongjiang, Liaoning, Hebei, Heinan, Sichuan provinces. They are collected in Spring and Autumn. The plants may be dried in the sunlight after removing stovers, fibrous roots and soils, or dried after piling them together. In general, when they become reddish yellow or yellowish gray they are scattered and dried in the sunlight.
[11] The plants have been used in oriental medicine for the purpose of eliminating
'wind'(a term in oriental medicine indicating a severe intermittent headache), 'damp'( a term in oriental medicine indicating a patient with damp syndrome), harmonize 'acupoint '( a term in oriental medicine indicating acupoint small pools of the circulating Gi and blood of channels and viscera where acupuncture or moxibustion is applied), releasing heat by releasing muscles and tendons and urinating. Therefore, the plants have been used for the treatment of paralytic pain, musculoskeletal cramps, jaundice, bloody stool (hematochezia), urination disorder. The major ingredients are known to contain ingredients such as gentianine, gentianidine, gentianol, gen- tiopicroside and the like. However, the role of the Gentianae macrophyllae radix regarding its therapeutic treatment of dermatological diseases has not been reported (Encyclopedia of Chinese Medicine, Jungdam Publishing Co., Ltd., pp. 5171-5177; 1998, Standards of Natural Drug Not Listed in Korea Pharmacopoeia, Korea Medical Index Co., Ltd., p. 352; 1988].
[12]
Disclosure
[13]
[14] The present invention relates to a therapeutic pharmaceutical agent comprising an extract of Gentianae macrophyllae radix as an active ingredient for the treatment of epidermal hyperplasia.
[15] The present invention is described in detail herein below.
[16] In one aspect, the present invention relates to an extract of crude Gentianae macrophyllae radix having an excellent inhibitory effect on epidermal proliferation of skin thus being useful for the prevention and treatment of dermatological diseases such as psoriasis.
[17] In another aspect, the present invention relates to a method of preparing an extract of crude Gentianae macrophyllae radix comprising:
[18] 1) a) extracting Gentianae macrophyllae radix under reflux using water or an aqueous alcohol solution in the amount of 10-15 times of the weight of the Gentianae macrophyllae radix, filtering the mixture;
[19] b) adding water or an aqueous alcohol solution to the resulting residue thereto in the amount of 7-12 times of the weight of the Gentianae macrophyllae radix, heating the mixture, reextracting the mixture, filtering the mixture;
[20] c) combining the resulting filtrate obtained in step b) with the filtrate obtained in step a), and filtering the mixed filtrate;
[21] 2) fractionating layers of the mixed filtrate obtained in the above step 1) using an equal amount of a low grade alcohol or a nonpolar solvent, and concentrating under reduced pressure at 60 - 70 ° C; and
[22] 3) performing azeotropic concentration of the above concentrate obtained in step 2) with water in the amount of 25-50 times of the weight of the above concentrate obtained in step 2), suspending the resulting concentrate homogeneously in an equal amount of water, and performing lyophilization.
[23] The above process is described in more detail herein below. In the above process,
Gentianae macrophyllae radix is added with water or an aqueous alcohol solution and extracted under reflux for 2-5 hours. The amount of water used is preferably in the range of 10-15 times of the weight of the Gentianae macrophyllae radix. The mixture undergoes filtration and the resulting filtrate is collected. Then, water or an aqueous alcohol solution in the amount of 7-12 times of the weight of the Gentianae macrophyllae radix is added to the resulting residue, and the mixture is heated. The mixture is reextracted for 2-5 hours, filtered and the resulting filtrate is combined with the filtrate obtained previously thereby increasing the extraction efficiency.
[24] Here, if the amount of water is not sufficient it will make stirring difficult and
decrease the solubility of the extract thus decreasing the extraction efficiency. In contrast, if the amount of water is excessive it will increase the amount of the low grade alcohol and the nonpolar solvent to be used in the subsequent purification step thus increasing cost and may also raise problems in proceeding the process.
[25] In the present invention, extraction is performed twice, i.e., first extraction and re- extraction. This is because a single extraction in the case of a large scale production of extract may not guarantee relatively high extraction efficiency due to a great loss in water content contained in the crude drug itself during the extraction process, and by conducting a reextraction the resulting extract efficiency can be greatly increased.
[26] The double extraction, i.e., performing first extraction and reextraction, results in collection of about 80-90% of the total amount of extract, while an extraction of 3 times or more is found not economical.
[27] The extract obtained by the double extraction using water or an aqueous alcohol solution is filtered and concentrated. Then impurities such as unnecessary proteins, polysaccharides, and fatty acids contained in the resulting concentrated filtrate are purified. In the present invention, the filtrate is purified by fractionation of the filtrate 2-4 times and obtaining a solvent fraction using a low grade alcohol or a nonpolar solvent which is equal in amount to that of the filtrate.
[28] A low grade alcohol is preferably a C1-C6 alcohol, more preferably butyl alcohol, propyl alcohol and isopropyl alcohol.
[29] A nonpolar solvent may be selected from the group consisting of ethyl acetate, dichloro methane, chloroform, carbon tetrachloride, and methylethylketone.
[30] In case the amount of the low grade alcohol or the nonpolar solvent is less than that of the filtrate, it forms granules from unnecessary components such as fatty acid thereby preventing a smooth separation of layers and also decreasing the content of active ingredients contained in the extract.
[31] The fractions of a low grade alcohol or a nonpolar solvent obtained as a result of fractionation are concentrated under reduced pressure at 60-70 ° C, and the residual solvent is eliminated. Thus obtained concentrate undergoes azeotropic concentration 2-3 times using water in the amount of 25-50 times of the total amount of the concentrate, and then suspended homogeneously in an equal volume of water.
[32] The purpose of using water in performing azeotropic concentration in this process is to effectively control the amount of the residual low grade alcohol for use of a crude drug extract as a source for a pharmaceutical agent.
[33] The above extract then undergoes lyophilization and the final extract in the form of powder is obtained. The extract has an excellent inhibitory effect on epidermal proliferation and is thus expected to be useful as a therapeutic pharmaceutical agent for the prevention and treatment of dermatological diseases such as psoriasis.
[34] In an embodiment of the present invention, the extract of Gentianae macrophyllae radix prepared according to the present invention is formulated in the form of tablets, capsules, injections and the like.
[35] In preparing tablets, the ratio between the combined amount of excipients, such as lactose, microcrystalline cellulose, magnesium stearate, and the amount of the above extract is preferred to be 2: 1 to attain a desired pharmaceutical activity for the prevention and treatment of dermatological diseases.
[36] Crude drugs themselves may be directly used as pharmaceutical agents. However, they may be combined with pharmaceutically acceptable additives such as a carrier, a forming agent, or a diluent to be prepared in the form of powder, granules, capsules, injections and the like.
[37] The extract of Gentianae macrophyllae radix has been long used as a food or an oriental medicine. There has been no particular limitation on its dosage but its dosage may vary depending on the rate of body absorption, body weight, age, sex, health conditions, dosage time, type of administration, excretion rate, seriousness of diseases of a subject. In general, the extract of Gentianae macrophyllae radix is preferably administered about 0.1 - 10 mg/kg. Therefore, the extract comprising the active ingredient of the present invention may be manufactured in consideration of the effective dosage. Further, the formulated unit dosage prepared thereof can be administered once or a few times at regular intervals daily by means of specialized administration, upon necessity, according to the advice and/or the request of a specialist or a supervisor who monitors and supervises drug administration.
[38]
Best Mode
[39]
[40] The present invention is described in more details with reference to the following examples. However, they should not be construed as limiting the scope of the present invention.
[41]
[42] Preparation Example 1 : Preparation of an Extract of Gentianae macrophyllae radix
[43] Two hundred fifty grams of crude Gentianae macrophyllae radix, minced to a size of about 3.0 cm, was homogeneously mixed, added with 2 L of water, and heat extracted for 5 hours while stirring. The extract was filtered and the filtrate was collected. The resulting residue was added with 2 L of water and heat extracted for 3 hours and filtered to obtain a second filtrate. The two filtrates were combined and concentrated to 1 L, which then underwent separation of layers 3 times by adding an equal amount of water-saturated n-butyl alcohol. The n-butyl alcohol was recovered and con-
centrated under reduced pressure at 65 ° C until all crude drugs were completely dried. After most of n-butyl alcohol and water were evaporated, the resultant was added with 0.1 L of water and underwent azeotropic concentration 2 times, resuspended in equal amount of distilled water, lyophilized and finally obtained the extract of Gentianae macrophyllae radix in the form of powder.
[44]
[45] Preparation Example 2 : Preparation of an Extract of Gentianae macrophyllae radix
[46] Two hundred fifty grams of crude Gentianae macrophyllae radix was washed with water to remove impurities, dried, added with 2L of 50%(v/v) ethanol solution and then extracted under reflux for 6 hours while stirring. The extract was filtered and then collected. The remaining residue was added with 1.5 L of 50%(v/v) ethanol solution, and then heat extracted for 3 hours. The two filtrates were combined and concentrated to 1 L, which then underwent separation of layers 3 times by adding an equal amount of water-saturated n-butyl alcohol. The n-butyl alcohol was recovered and concentrated under reduced pressure at 65 ° C until all crude drugs were completely dried. After most of n-butyl alcohol and water were evaporated, the resultant was added with 0.3 L of water and underwent azeotropic concentration 2 times, resuspended in equal amount of distilled water, lyophilized and finally obtained the extract of Gentianae macrophyllae radix in the form of powder.
[47]
[48] Example 1: Test of Acute Toxicity of Oral Administrative Formulation in Rats
[49] A test of acute toxicity was performed by using 6-week-old specific pathogen free
(SPF) SD rats as follows.
[50] Each group consisted of 2 rats. They were orally respectively administered with the extract of Gentianae macrophyllae radix prepared in Preparation Examples 1 and 2 with a dosage of 1 g/kg/mL once. After the administration, the rats were observed of their deaths, clinical symptoms, and weight changes. Further, hematological test and hematobiochemical test were conducted and abnormalities on abdominal and pectoral organs were observed by naked eyes via autopsies. As a result, no significant clinical symptoms or dead rats were found, and also no toxicity was observed from the weight changes, blood test, hematobiochemical test and autopsies. In summary, there was no toxicity observed in experimental rats by the administration of the extract of Gentianae macrophyllae radix when used up to dosage of 2,000 mg/kg. Its lethal dosage (LD ) for oral administration was shown to be greater than 2,000 mg/kg thus showing the safety of the above extract.
[51]
[52] Formulation Example 1: Preparation of Tablets
[53] Tablets for oral administration were manufactured by using the extract of crude
Gentianae macrophyllae radix of the present invention via wet granulation and dry granulation according to the following formulation. [54]
[55] [Formulation]
[56] extract of Gentianae macrophyllae radix 200 mg
[57] Light Anhydrous Silicic Acid 10 mg
[58] magnesium stearate 2 mg
[59] microcrystalline cellulose 50 mg
[60] sodium starch glycolate 25 mg
[61] corn starch 113 mg
[62] anhydrous ethanol adequate [63]
[64] Formulation Example 2: Preparation of Ointments
[65] Ointments were manufactured by using the extract of crude Gentianae macrophyllae radix of the present invention according to the following formulation. [66]
[67] [Formulation]
[68] extract of Gentianae macrophyllae radix 5 g
[69] cetylpalmitate 20 g
[70] cetanol 40 g
[71] stearyl alcohol 40 g
[72] isopropyl myristate 80 g
[73] sorbitan monostearate 20 g
[74] polysolvate 60 g
[75] propyl parahydroxy benzoic acid 1 g
[76] methyl parahydroxy benzoic acid 1 g
[77] phosphate and distilled water adequate amount [78]
[79] Formulation Example 3: Preparation of Injections
[80] An injection was prepared by using the extract of crude Gentianae macrophyllae radix prepared according to the present invention using the following formulation. [81]
[82] [Formulation]
[83] extract of Gentianae macrophyllae radix 100 mg
[84] mannitol 180 mg
[85] Na 2HPO 4 - 12H2O 25 mg
[86] water for injection 2974 mg
[88] Formulation Example 4: Preparation of Topical Formulation
[89] Epidermal formulation was prepared by using the extract of crude Gentianae macrophyllae radix prepared according to the present invention.
[90]
[91] [Formulation 1]
[92] extract of Gentianae macrophyllae radix 0.4 g
[93] sodium polyacrylate 1.3 g
[94] glycerine 3.6 g,
[95] aluminum hydroxide 0.04 g
[96] methyl paraben 0.2 g
[97] water 14.0 g
[98]
[99] [Formulation 2]
[100] extract of Gentianae macrophyllae radix 0.8 g
[101] propylene glycol 1.6 g
[102] liquid paraffin 0.8 g
[103] isopropyl myristate 0.4 g
[104] Gelba 1430 16.4 g
[105]
Industrial Applicability
[106]
[107] As stated above, the extract of Gentianae macrophyllae radix prepared according to the present invention has an excellent inhibitory effect on epidermal hyperplasia and is thus speculated to be very useful for the prevention and treatment of dermatological diseases such as psoriasis.
[108] The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated by those skilled in the art that changes may be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims
[1] A therapeutic pharmaceutical agent for the treatment of epidermal hyperplasia of skin comprising an extract of Gentianae macrophyllae radix as an active ingredient.
[2] The therapeutic pharmaceutical agent according to claim 1, wherein said derma- tological disease caused by epidermal hyperplasia of skin cells is psoriasis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2005-0134720 | 2005-12-30 | ||
| KR1020050134720A KR20070071357A (en) | 2005-12-30 | 2005-12-30 | An extract of gentianae macrophyllae radix for the treatment of dermatological disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2007078117A1 true WO2007078117A1 (en) | 2007-07-12 |
Family
ID=38228416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2006/005868 WO2007078117A1 (en) | 2005-12-30 | 2006-12-29 | Extract of gentianae macrophyllae radix for the treatment of dermatological diseases |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR20070071357A (en) |
| TW (1) | TW200733969A (en) |
| WO (1) | WO2007078117A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000043996A (en) * | 1998-12-29 | 2000-07-15 | 조민호 | Extraction and purification method of active substance from gentianae macrophyllae radix and crudedrug composition comprising the same |
| KR20060102620A (en) * | 2005-03-24 | 2006-09-28 | 한국 한의학 연구원 | Composition containing gentianae macrophyllae radix extract for treatment hypersensitive skin disease |
-
2005
- 2005-12-30 KR KR1020050134720A patent/KR20070071357A/en not_active Application Discontinuation
-
2006
- 2006-12-29 TW TW095149852A patent/TW200733969A/en unknown
- 2006-12-29 WO PCT/KR2006/005868 patent/WO2007078117A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000043996A (en) * | 1998-12-29 | 2000-07-15 | 조민호 | Extraction and purification method of active substance from gentianae macrophyllae radix and crudedrug composition comprising the same |
| KR20060102620A (en) * | 2005-03-24 | 2006-09-28 | 한국 한의학 연구원 | Composition containing gentianae macrophyllae radix extract for treatment hypersensitive skin disease |
Non-Patent Citations (2)
| Title |
|---|
| CHINESE JOURNAL OF MODERN DEVELOPMENTS IN TRADITIONAL MEDICINE, vol. 9, no. 3, March 1989 (1989-03-01), pages 156 - 157 * |
| DATABASE MEDLINE [online] YUAN Z.Z. ET AL.: "Observation on the treatment of systemic lupus erythematous with a Gentiana macrophylla complex tablet and a minimal dose of prednisone", XP003015388, Database accession no. (NLM2736700) * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200733969A (en) | 2007-09-16 |
| KR20070071357A (en) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8652537B2 (en) | Herbal drug composition for cartilage protection | |
| KR101609535B1 (en) | Anti-arthritis and cartilage protective herbal preparations containing reduced cucurbitacin B | |
| TW201321010A (en) | Plectranthus amboinicus fraction having anti-arthritis activity | |
| CN115414423A (en) | Traditional Chinese medicine composition for treating eczema and application of traditional Chinese medicine composition in preparation of itching-relieving and healing-promoting cream | |
| WO2007078117A1 (en) | Extract of gentianae macrophyllae radix for the treatment of dermatological diseases | |
| JP3828163B2 (en) | Anti-inflammatory, anti-itch agent | |
| CN111374970B (en) | Composition with anti-colitis activity and application thereof | |
| EP2124980A1 (en) | Composition comprising trachelospermi caulis and pyrola japonica extracts for the treatment and prevention of inflammatory diseases | |
| KR102167530B1 (en) | Composition comprising plant extract effective for skin health | |
| JP5231244B2 (en) | Mokubetsu extract useful for prevention and treatment of gastritis or gastric ulcer and momordica saponin I isolated therefrom | |
| CA2918291C (en) | Use of plant extracts against herpes simplex virus | |
| WO2016162489A1 (en) | Treatment of nail disorder with an indigo naturalis or indigo-producing plant extract | |
| KR101096574B1 (en) | Pharmaceutical composition for preventing or treating osteoporosis comprising Vitis vinifera pip extract | |
| KR101026524B1 (en) | A medicinal herbs composition for protective stomach and intestines | |
| JP2009520020A5 (en) | ||
| KR20050121094A (en) | Preventive and curative extracts from siegesbeckiae herba for respiratory organ disease | |
| KR101086258B1 (en) | Preventive and curative extracts from medicinal plants and their composition for respiratory organ disease | |
| KR20060037120A (en) | Preventive and curative extracts from sophorae radix for respiratory organ disease | |
| CN1159038C (en) | 'Shuanghuang Yupi' cream for skin healing | |
| CN116870076B (en) | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof | |
| CN109303790B (en) | Medical application of caper or caper extract | |
| KR100858733B1 (en) | Cartilage protective ingredients from Trichosanthes kirilowii | |
| JPH04208221A (en) | Lipoxygenase inhibitor | |
| KR101086256B1 (en) | Preventive and curative extracts from Gentianae macrophyllae radix for respiratory organ disease | |
| KR20030082764A (en) | Articulation protective ingredients from medicinal plant and their composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06835568 Country of ref document: EP Kind code of ref document: A1 |